What is Sutro Biopharma's D&A?

Sutro Biopharma (STRO) reported D&A of $1.28M in Q1 2026.

How has Sutro Biopharma's D&A changed year-over-year?

Sutro Biopharma's D&A decreased by 32.7% year-over-year, from $1.9M to $1.28M.

What is the long-term trend for Sutro Biopharma's D&A?

Over 4 years (2021 to 2025), Sutro Biopharma's D&A has grown at a 10.9% compound annual growth rate (CAGR), from $4.84M to $7.32M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Sutro Biopharma STRO D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

RegenxbioRGNX

$3.86M-2.5%

XencorXNCR

$2.57M-4.7%

AnaptysBio, Inc.ANAB

$130K-11.0%

SchrodingerSDGR

$1.48M-7.1%

Roivant SciencesROIV

$638K-55.2%

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's D&A?: Sutro Biopharma (STRO) reported D&A of $1.28M in Q1 2026.
How has Sutro Biopharma's D&A changed year-over-year?: Sutro Biopharma's D&A decreased by 32.7% year-over-year, from $1.9M to $1.28M.
What is the long-term trend for Sutro Biopharma's D&A?: Over 4 years (2021 to 2025), Sutro Biopharma's D&A has grown at a 10.9% compound annual growth rate (CAGR), from $4.84M to $7.32M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.